Peter Ball
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Ball has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
D. E. Low
1 shared publicationE. Rubinstein
1 shared publicationF. Baquero
1 shared publicationG Patou
1 shared publicationG Tillotson
1 shared publicationGlenn S. Tillotson
Replidyne Inc., Milford, CT, USA
1 shared publication
Latest Publications
- 31 December 2007
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 30, 139-141
Conclusions: the future of antimicrobial therapy – Augmentin® and beyond
- 31 December 2007
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 30, 139-141
Conclusions: the future of antimicrobial therapy – Augmentin® and beyond
- 1 December 2007
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 30, 113-117
The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
- 1 December 2007
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 30, 113-117
The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
- Open Access
- 26 June 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 60 (3) , 464-469
Meeting report: Fourth Forum on Respiratory Tract Infections, Sitges, Spain, 8–11 February 2007
Over 420 delegates participated in this, the fourth of a biennial series of scientific meetings, drawing from 30 or more nations and encompassing the specialties of infectious diseases, clinical microbiology, pulmonary and general medicine and Industry inter alia. The 2007 Forum was chaired by Professors Antoni Torres Marti, Giuliana Gialdroni Grassi and Dr Peter Ball and received academic endorsement from the British Society for Antimicrobial Chemotherapy (BSAC), Italian Society for Chemotherapy, Spanish Pulmonology Society, Paul Ehrlich Society and the Société de Pneumologie de Langue Français. The Scientific Programme was scientifically and financially supported by the BSAC and a consortium of pharmaceutical companies. Discussion focused on key contemporary issues in respiratory tract infection (RTI), including the impact of antibiotic resistance on clinical outcomes and the continuing need for antibiotic conservation via evolving guidelines, the challenges of avian influenza, nosocomial RTIs and the emergence of new pathogens, e.g. community-acquired methicillin-resistant Staphylococcus aureus, novel antimicrobial agents, disease definitions (e.g. healthcare-associated pneumonia) and therapeutic assessment criteria, such as patient-reported outcome measures, in improving RTI management. The entire meeting was granted CME recognition (18 sessions) by the European Accreditation Council for continuing medical education.
- 26 June 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 60 (3) , 464-469
Open AccessMeeting report: Fourth Forum on Respiratory Tract Infections, Sitges, Spain, 8–11 February 2007
Over 420 delegates participated in this, the fourth of a biennial series of scientific meetings, drawing from 30 or more nations and encompassing the specialties of infectious diseases, clinical microbiology, pulmonary and general medicine and Industry inter alia. The 2007 Forum was chaired by Professors Antoni Torres Marti, Giuliana Gialdroni Grassi and Dr Peter Ball and received academic endorsement from the British Society for Antimicrobial Chemotherapy (BSAC), Italian Society for Chemotherapy, Spanish Pulmonology Society, Paul Ehrlich Society and the Société de Pneumologie de Langue Français. The Scientific Programme was scientifically and financially supported by the BSAC and a consortium of pharmaceutical companies. Discussion focused on key contemporary issues in respiratory tract infection (RTI), including the impact of antibiotic resistance on clinical outcomes and the continuing need for antibiotic conservation via evolving guidelines, the challenges of avian influenza, nosocomial RTIs and the emergence of new pathogens, e.g. community-acquired methicillin-resistant Staphylococcus aureus, novel antimicrobial agents, disease definitions (e.g. healthcare-associated pneumonia) and therapeutic assessment criteria, such as patient-reported outcome measures, in improving RTI management. The entire meeting was granted CME recognition (18 sessions) by the European Accreditation Council for continuing medical education.
- 1 May 2004
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 23 (5) , 421-429
A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context
- 1 May 2004
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 23 (5) , 421-429
A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context
- 1 November 2003
- Published by Elsevier in Current Therapeutic Research
- Vol. 64 (9) , 646-661
Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review
- 1 November 2003
- Published by Elsevier in Current Therapeutic Research
- Vol. 64 (9) , 646-661
Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review
- 1 May 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 51 (90001) , 21-27
Adverse drug reactions: implications for the development of fluoroquinolones
Quinolone antibacterials, originally derived from anti-malarial compounds, have been developed through side-chain and nuclear manipulation, notably by piperazine and other mono- or bi-cyclic substitutions at the 7 position (giving anti-pseudomonal activity and greater anti-Gram-negative activity) and fluorination at various sites (giving increased anti-Gram-positive activity). The class has now been in clinical use for 40 years. Increased activity has not been without cost: for example, specific idiosyncratic reactions have consigned agents such as the 1-(2,4)-difluorophenyl compounds, such as temafloxacin (haemolytic uraemic syndrome) and trovafloxacin (hepatotoxic reactions), to restriction, suspension or withdrawal. Class adverse drug reactions (ADRs), variable in frequency and severity within the group, have significantly affected individual groups of compounds, such as the 8-chloro derivatives (Bay y 3118, clinafloxacin and sitafloxacin), which, whilst extremely potent, are also highly phototoxic and have largely been discarded.
- 1 May 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 51 (90001) , 21-27
Adverse drug reactions: implications for the development of fluoroquinolones
Quinolone antibacterials, originally derived from anti-malarial compounds, have been developed through side-chain and nuclear manipulation, notably by piperazine and other mono- or bi-cyclic substitutions at the 7 position (giving anti-pseudomonal activity and greater anti-Gram-negative activity) and fluorination at various sites (giving increased anti-Gram-positive activity). The class has now been in clinical use for 40 years. Increased activity has not been without cost: for example, specific idiosyncratic reactions have consigned agents such as the 1-(2,4)-difluorophenyl compounds, such as temafloxacin (haemolytic uraemic syndrome) and trovafloxacin (hepatotoxic reactions), to restriction, suspension or withdrawal. Class adverse drug reactions (ADRs), variable in frequency and severity within the group, have significantly affected individual groups of compounds, such as the 8-chloro derivatives (Bay y 3118, clinafloxacin and sitafloxacin), which, whilst extremely potent, are also highly phototoxic and have largely been discarded.
- Open Access
- 1 January 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 49 (1) , 31-40
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
Widespread, increasing antibiotic resistance amongst the major respiratory pathogens has compromised traditional therapy of the major infective respiratory syndromes, including bacterial pneumonia and acute exacerbations of chronic bronchitis. Guidelines for antibiotic prescribing dating from the 1980s to 1990s, which attempted to address such problems, were commonly too prescriptive and difficult to apply, and took little account of end-user practice or locally prevalent resistance levels. Further confusion was caused by conflicting recommendations emanating from differing specialty groups. The evidence that such guidelines benefited either clinical outcomes or treatment costs has been disputed. They have probably had little effect on resistance emergence. We report the recommendations of an independent, multi-national, inter-disciplinary group, which met to identify principles underlying prescribing and guideline formulation in an age of increasing bacterial resistance. Unnecessary prescribing was recognized as the major factor in influencing resistance and costs. Antibiotic therapy must be limited to syndromes in which bacterial infection is the predominant cause and should attempt maximal reduction in bacterial load, with the ultimate aim of bacterial eradication. It should be appropriate in type and context of local resistance prevalence, and optimal in dosage for the pathogen(s) involved. Prescribing should be based on pharmacodynamic principles that predict efficacy, bacterial eradication and prevention of resistance emergence. Pharmacoeconomic analyses confirm that bacteriologically more effective antibiotics can reduce overall management costs, particularly with respect to consequential morbidity and hospital admission. Application of these principles should positively benefit therapeutic outcomes, resistance avoidance and management costs and will more accurately guide antibiotic choices by both individuals and formulary/guideline committees.
- 1 January 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 49 (1) , 31-40
Open AccessAntibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
Widespread, increasing antibiotic resistance amongst the major respiratory pathogens has compromised traditional therapy of the major infective respiratory syndromes, including bacterial pneumonia and acute exacerbations of chronic bronchitis. Guidelines for antibiotic prescribing dating from the 1980s to 1990s, which attempted to address such problems, were commonly too prescriptive and difficult to apply, and took little account of end-user practice or locally prevalent resistance levels. Further confusion was caused by conflicting recommendations emanating from differing specialty groups. The evidence that such guidelines benefited either clinical outcomes or treatment costs has been disputed. They have probably had little effect on resistance emergence. We report the recommendations of an independent, multi-national, inter-disciplinary group, which met to identify principles underlying prescribing and guideline formulation in an age of increasing bacterial resistance. Unnecessary prescribing was recognized as the major factor in influencing resistance and costs. Antibiotic therapy must be limited to syndromes in which bacterial infection is the predominant cause and should attempt maximal reduction in bacterial load, with the ultimate aim of bacterial eradication. It should be appropriate in type and context of local resistance prevalence, and optimal in dosage for the pathogen(s) involved. Prescribing should be based on pharmacodynamic principles that predict efficacy, bacterial eradication and prevention of resistance emergence. Pharmacoeconomic analyses confirm that bacteriologically more effective antibiotics can reduce overall management costs, particularly with respect to consequential morbidity and hospital admission. Application of these principles should positively benefit therapeutic outcomes, resistance avoidance and management costs and will more accurately guide antibiotic choices by both individuals and formulary/guideline committees.
- 1 September 2001
- Published by Elsevier in Seminars in Respiratory Infections
- Vol. 16 (3) , 215-224
Future of the quinolones☆
- 1 September 2001
- Published by Elsevier in Seminars in Respiratory Infections
- Vol. 16 (3) , 215-224
Future of the quinolones☆
- 1 January 2001
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 13 (3) , 288-298
Efficacy of Gemifloxacin in Acute Exacerbations of Chronic Bronchitis: a Randomised, Double-Blind Comparison with Trovafloxacin
This randomised, double-blind, double-dummy, multinational study compared the efficacy and safety of gemifloxacin with trovafloxacin in the treatment of acute exacerbations of chronic bronchitis. There were 617 patients randomised: 303 to gemifloxacin and 314 to trovafloxacin. Clinical success rates at follow-up (clinical per-protocol population) were 91.5% for gemifloxacin and 87.6% for trovafloxacin. For the intent-to-treat population, the clinical efficacy of gemifloxacin was statistically significantly superior to that of trovafloxacin. In general, the in vitro activity of gemifloxacin against the major respiratory bacterial pathogens was superior to that of other antibiotics tested. Per-patient bacteriological success rates at follow-up (bacteriology per-protocol population) were 86.8% for gemifloxacin and 82.4% for trovafloxacin. Both agents were well tolerated. The clinical and bacteriological efficacy of a once-daily 5-day course of gemifloxacin is at least as good as that of a similar regimen of trovafloxacin in the treatment of acute exacerbations of chronic bronchitis.
- 1 January 2001
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 13 (3) , 288-298
Efficacy of Gemifloxacin in Acute Exacerbations of Chronic Bronchitis: a Randomised, Double-Blind Comparison with Trovafloxacin
This randomised, double-blind, double-dummy, multinational study compared the efficacy and safety of gemifloxacin with trovafloxacin in the treatment of acute exacerbations of chronic bronchitis. There were 617 patients randomised: 303 to gemifloxacin and 314 to trovafloxacin. Clinical success rates at follow-up (clinical per-protocol population) were 91.5% for gemifloxacin and 87.6% for trovafloxacin. For the intent-to-treat population, the clinical efficacy of gemifloxacin was statistically significantly superior to that of trovafloxacin. In general, the in vitro activity of gemifloxacin against the major respiratory bacterial pathogens was superior to that of other antibiotics tested. Per-patient bacteriological success rates at follow-up (bacteriology per-protocol population) were 86.8% for gemifloxacin and 82.4% for trovafloxacin. Both agents were well tolerated. The clinical and bacteriological efficacy of a once-daily 5-day course of gemifloxacin is at least as good as that of a similar regimen of trovafloxacin in the treatment of acute exacerbations of chronic bronchitis.
- 30 November 2000
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 16 (3) , 263-272
New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
- 30 November 2000
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 16 (3) , 263-272
New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?